GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GKOS is a good long-term buy for a beginner with $50,000-$100,000 available, but not an aggressive short-term chase at the current pre-market level. The company has strong revenue growth, improving product adoption, and broad analyst support, which outweigh the overbought technical condition for a patient long-term investor. Since the user is unwilling to wait for an ideal entry, this is still a buy now for long-term allocation, though new money should be entered in stages rather than all at once.
The trend is bullish. MACD is positive and expanding, and the moving averages are aligned constructively with SMA_5 above SMA_20 above SMA_200, which supports an established uptrend. However, RSI_6 at 83.973 is overbought, so the stock is extended in the very short term. Price is trading near resistance at 147.511, above the pivot 127.426 and above R1 139.841, which confirms strength but also suggests limited immediate upside after the recent run. Pre-market price is 143.5, slightly down 0.12%, with the broader market mildly positive.
["Q1 2026 revenue hit a record $150.6M, up 41.16% YoY.", "iDose TR contributed about $54M, up 58% YoY, showing strong product adoption.", "Epioxa is expanding launch coverage, already reaching areas serving about 65% of the U.S. population with room to expand to 95%.", "Gross margin remains very strong at 84% in Q1, with guidance to maintain 84% to 86% for the full year.", "Analyst sentiment is broadly positive, with multiple firms raising price targets after strong Q1 results.", "Hedge funds are buying aggressively, with buying up 318.02% over the last quarter."]
["RSI is overbought, indicating the stock may be stretched after the recent run-up.", "Net income and EPS are still negative, so profitability has not yet turned positive.", "Recent price action suggests near-term upside may be less attractive after the sharp move higher.", "EPS estimate revisions were mixed over the past three months, with more downward than upward revisions before earnings.", "The stock trend model suggests a high probability of a small pullback over the next day and week."]
In Q1 2026, Glaukos delivered strong growth: revenue rose 41.16% YoY to $150.6M, led by U.S. glaucoma franchise sales of $93.5M and iDose TR revenue of about $54M. Gross margin was strong at 77.86% in the snapshot data and was also reported at 84% in the news summary, showing excellent operating leverage and product economics. Net income remained negative at -$19.8M and EPS was -0.34, so the company is still investing for growth. Overall, the latest quarter was clearly strong on sales growth and margin profile, which is favorable for long-term investors.
Wall Street sentiment is positive and improving. Goldman Sachs, Stifel, JPMorgan, Needham, BTIG, Citi, and Wells Fargo all raised price targets recently, and all maintained Buy/Overweight-type ratings. The latest round of upgrades came after strong Q1 results, accelerated iDose adoption, and early traction for Epioxa. The pros view is that Glaukos has durable growth from new products and expanding coverage; the cons view is that the stock is already priced for strong execution and is technically extended after the earnings run-up. No recent politician or influential figure trading data is available, and there is no recent congress trading activity to assess.
